

Submitted by:

Katherine Hsu, PharmD
Associate Director, Medical Information Services
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
Phone: (425) 590-7925
Email: Katherine.Hsu@sppirx.com

Date of Request: May 12, 2010
NCCN Guidelines Panel: Non-Hodgkin's Lymphoma

On behalf of the Spectrum Pharmaceuticals, Inc, I respectfully request that the NCCN Guideline Panel for treatment of non-Hodgkin's lymphoma to review the enclosed publications for consideration of modifying the NCCN Guidelines to include Zevalin therapy for use in diffuse large B-cell lymphoma (DLBCL).

Specific Changes: To include Zevalin therapeutic regimen as an option for treating DLBCL.

The FDA approved indications for Zevalin therapeutic regimen are for the treatment of patients with:¹

- relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL)
- previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy

The Zevalin therapeutic regimen is not approved for use in DLBCL. However, there have been publications in both the previously untreated and relapsed/refractory patients with DLBCL.²⁻⁹ Studies that reported response rates have cited overall response rates (ORR) of >95% in previously untreated patients. In the relapsed/refractory setting, the ORR ranged from 19% to 58%.^{7,8} Additionally, a group of investigators reported a duration of response of 85 months in a relapsed DLBCL patient treated with Zevalin.⁹ Grade 3 or 4 hematologic toxicity was observed both in the previously untreated and the relapsed/refractory patients.

Thank you for your review of the enclosed publications.

Sincerely,

A handwritten signature in black ink, appearing to read 'Katherine Hsu', with a stylized flourish at the end.

Katherine Hsu, PharmD

References

1. Zevalin [package insert]. Irvine, CA; Spectrum Pharmaceuticals, Inc.
2. Zinzani PL, Fina M, Tani M, et al. A phase II trial of rituximab-CHOP chemotherapy followed by yttrium-90 (90Y) ibritumomab tiuxetan (90Y-IT) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. *Blood* 2009;114. Abstract 2720.
3. Hamlin PA, Moskowitz CH, Wegner B, et al. Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL. Oral presentation at: International Conference on Malignant Lymphoma Meeting; June 5, 2008; Lugano, Switzerland.
4. Yang D-H, Kim WS, Suh C, et al. Phase II trial of 90Y-ibritumomab tiuxetan as consolidation after 6th R-CHOP chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. *Blood* 2009;114. Abstract 3751.
5. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. *Ann Oncol* 2008;19:769-73.
6. Venugopal P, Gregory S, Obrien T, et al. Phase II study of 2-weekly CHOP + rituximab followed by yttrium 90 ibritumomab tiuxetan (Zevalin) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). *Blood* 2007;110. Abstract 4507.
7. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. *Blood* 2007;110(1):54-8.
8. Gordon LI, Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab tiuxetan (ZEVALIN®) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity [Abstract]. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida May 18-21, 2002; 21:266a,#1061
9. Perrotti AP, Niscola P, Boemi S, et al. Long-lasting remission of a relapsed large cell non-Hodgkin's lymphoma by Y90 ibritumomab tiuxetan as salvage therapy. *Tumori*. 2009;95(1):129-30